Andrey Vorobyov, Governor of the Moscow Region, has visited the Petrovax Pharm manufacturing complex to hold a meeting with managers of pharmaceutical companies. The participants discussed the problems of and prospects for developing the regional pharmaceutical industry, the issues related to drug safety and pharmaceutical independence, ensuring the Russian healthcare system is supplied with modern drugs.
According to the Governor, the national medical security is highly sought, whereas a quarter of all Russian pharmaceutical production capacity is concentrated in the Moscow Region. Therefore, regional businesses not only provide hundreds of jobs but also develop technology within the country.
The meeting participants drew the Governor’s attention to increased drug availability for patients; in particular, the registration period for new drugs and support offered to manufacturers through public procurement under offset contracts.
Mikhail Tsyferov, Petrovax Pharm President, noted that amendments to laws adopted in 2022, enabling the offset contracting mechanism to secure the needs of two or more constituent entities of the Russian Federation, opened up new opportunities for investment projects.
During his visit, the Governor also spoke with the factory employees, asked them several questions about the company and their working conditions, about professional education and competencies, corporate development plans and export potential.
Mikhail Tsyferov, Company’s President, and Larisa Dukhina, Director of the Production Complex, spoke about the steps that Petrovax is taking to provide the Russian healthcare system with modern drugs and vaccines as well as to increase its export potential.
The Petrovax Pharm manufacturing complex based in Podolsk, Moscow Region, is one of the leading full-cycle biopharmaceutical enterprises in Russia and the largest biotech center in the Moscow Region. For 15 years now, it has produced millions of doses of drugs per year to provide patients with life-saving medicines and vaccines. In 2021, the company signed a cooperation agreement with the Government of the Moscow Region in order to improve the investment climate and the regional economy.
The company is implementing investment projects to expand its production. Thus, in 2024, it will complete constructing a pilot biotechnological production center for substances and genetically engineered drugs to be supplied not only to Russia but also to EurAsEC and Asia-Pacific region countries. In 2022, an investment project was launched in partnership with the South Korean company ISU Abxis for the localization of the full-cycle production of agalsidase beta (Fabagal) for the treatment of a rare condition, Fabry disease. Under this project, Petrovax Pharm will synthesize the substance and produce the finished dosage form.
The company’s products are part of the list of vital and essential drugs (VED) supplied under public contracts, including for the National Immunization Schedule of the Russian Federation and those of foreign countries. Petrovax produces and exports not only vaccines but also original drugs, such as Polyoxidonium® and Longidaza®, which demonstrated good results in the prevention and treatment of coronavirus infection and rehabilitation after COVID-19.